Systemic adjuvant therapies in renal cell carcinoma

Oncology Reviews

Volumn 6, Issue 2, 2012, Pages 145-152

  Buti, Sebastiano ^a   Bersanelli, Melissa ^a   Donini, Maddalena ^b   Ardizzoni, Andrea ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b CREMONA HOSPITAL   (Italy)

Author keywords

Adjuvant therapy; Immunotherapy; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; CAPECITABINE; DOXORUBICIN; EVEROLIMUS; FLUOROURACIL; GIRENTUXIMAB; GLUTAMATE CYSTEINE LIGASE; HEAT SHOCK PROTEIN; INTERLEUKIN 2; MEDROXYPROGESTERONE ACETATE; MULTIDRUG RESISTANCE PROTEIN 1; PAZOPANIB; PEGINTERFERON ALPHA2A; PLACEBO; SORAFENIB; SUNITINIB; THALIDOMIDE; UFT; VINBLASTINE; VITESPEN;

ANTIANGIOGENIC ACTIVITY; BOLUS INJECTION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CYTOTOXIC LYMPHOCYTE; DISTANT METASTASIS; DRUG EFFICACY; DRUG MEGADOSE; HEALTH CARE QUALITY; HUMAN; IMMUNE RESPONSE; KIDNEY CANCER; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; NATURAL KILLER CELL; NEPHRECTOMY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMIC THERAPY; TREATMENT OUTCOME;

EID: 84878640359     PISSN: 19705557     EISSN: 19705565     Source Type: Journal    
DOI: 10.4081/oncol.2012.e18     Document Type: Review

References (90)

1. Gupta K, Miller JD, Li JZ, et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 2008; 34: 193-205.
2. Jemal A, Siegel R, Ward E. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
3. Seer.cancer.gov [Internet]. SEER Stat Fact Sheets: kidney and renal pelvis [updated 2002 November 10]. http://seer.cancer.gov/statfacts/html/kidrp. html Accessed: March 20, 2012.
4. Brennan P, van der Hel O, Moore LE. Tobacco smoking, body mass index, hypertension, and kidney cancer risk in central and eastern Europe. Br J Cancer 2008; 99: 1912-5.
5. Chow WH, Gridley G, Fraumeni IF, Järvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med 2000; 343: 1305-11.
6. Benichou J, Chow WH, McLaughlin JK, et al. Population attributable risk of renal cell cancer in Minnesota. Am J Epidemiol 1998; 148: 424-30.
7. Gettman MT, Blute ML, Spotts B, et al. Pathologic staging of renal cell carcinoma: Significance of tumor classification with the 1997 TNM staging system. Cancer 2001; 91: 354-61.
8. Marszalek M, Meixl H, Polajnar M, et al. Laparoscopic and open partial nephrectomy: a matched-pair comparison of 200 patients. Eur Urol 2009; 181: 170-6.
9. Breda A, Finelli A, Janetschek G, et al. Complications of laparoscopic surgery for renal masses: prevention, management, and comparison with the open experience. Eur Urol 2009; 55: 836-50.
10. Garg S, Batura D, Biyani CS, Gill I. Laparoscopic surgery for cancers of the kidney: Long-term oncological efficacy. BJU Int 2008; 102: 1498-501.
11. Butler B P, Novick AC, Miller DP, et al. Management of small unilateral renal cell carcinomas: radical versus nephron-sparing surgery. Urology 1995; 45: 34-40.
12. Lerner SE, Hawkins CA, Blute ML, et al. Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery. J Urol 1996; 155: 1868-73.
13. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, (eds). AJCC Cancer Staging Manual. 6th Printing. Berlin: Springer Verlag; 2010.
14. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24.
15. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996; 335: 865-75.
16. Lam JS, Shvarts O, Leppert JT, et al. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol 2005; 173: 1853-62.
17. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Path 1982; 6: 655-63.
18. Kontak JA, Campbell SC. Prognostic factors in renal cell carcinoma. Urol Clin North Am 2003; 30: 467-80.
19. Patard JJ, Leray E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005; 23: 2763-71.
20. Dall'Oglio MF, Antunes AA, Sarkis AS, et al. Microvascular tumour invasion in renal cell carcinoma: the most important prognostic factor. BJU Int 2007; 100: 552-5.
21. Cheville JC, Lohse CM, Zincke H, et al. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003; 27: 612-24.
22. Frank I, Blute ML, Cheville JC, et al. A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma. J Urol 2003; 170: 2225-32.
23. Chowdhury S, Larkin JM, Gore ME. Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies. Eur J Cancer 2008; 44: 2152-61.
24. Kim S P, Weight CJ, Leibovich BC, et al. Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma. Urology 2011; 78: 1101-6.
25. Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res 2003; 9: 4641-52.
26. Leppert JT, Lam JS, Pantuck AJ, et al. Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma. BJU Int 2005; 96: 281-5.
27. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003; 9: 802-11.
28. Soyupak B, Erdogan S, inventors. MN/CA IX/CA9 and renal cancer prognosis. United States Patent: US 20090191557; 2009.
29. Patard J, Fergelot P, Karakiewicz PI, et al. Low CAIX expression and absence of VHL gene mutation are associated with tumour aggressiveness and poor survival. Int J Cancer 2008; 123: 395-400.
30. Finley DS, Pantuck AJ, Belldegrun AS. Tumor biology and prognostic factors in renal cell carcinoma. Oncologist 2011; 16 Suppl 2: 4-13.
31. Takahashi M, Rhodes DR, Furge KA, et al. Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci U S A 2001; 98: 9754-9.
32. Sorbellini M, Kattan MW, Snyder ME, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 2005; 173: 48-51.
33. Zisman A, Pantuck AJ, Dorey F, et al. Mathematical model to predict individual survival for patients with renal cell carcinoma. J Clin Oncol 2002; 20: 1368-74.
34. Frank I, Blute ML, Cheville JC. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002; 168: 2395-400.
35. Karakiewicz PI, Briganti A, Chu FK, et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol. 2007; 25(11): 1316-22.
36. Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003; 97: 1663-71.
37. Pichler M, Hutterer GC, Chromecki TF, et al. External validation of the Leibovich prognosis score for nonmetastatic clear cell renal cell carcinoma at a single European center applying routine pathology. J Urol 2011; 186: 1773-7.
38. Pichler M, Hutterer GC, Chromecki TF, et al. Prognostic value of the Leibovich prognosis score supplemented by vascular invasion for clear cell renal cell carcinoma. J Urol 2012; 187: 834-9.
39. Ficarra V, Novara G, Galfano A, et al. The 'Stage, Size, Grade and Necrosis' score is more accurate than the University of California Los Angeles Integrated Staging System for predicting cancer-specific survival in patients with clear cell renal cell carcinoma. BJU Int 2009; 103: 165-70.
40. Tan MH, Kanesvaran R, Li H, et al. Comparison of the UCLA Integrated Staging System and the Leibovich score in survival prediction for patients with nonmetastatic clear cell renal cell carcinoma. Urology 2010; 75: 1365-70.
41. Tan MH, Li H, Choong CV, et al. The Karakiewicz nomogram is the most useful clinical predictor for survival outcomes in patients with localized renal cell carcinoma. Cancer 2011; 117: 5314-24.
42. NCCN.org [Internet]. Clinical Practice Guidelines in Oncology (NCCN Guidelines). Version 1.2012. http://www.nccn.org/profes-sionals/physician-gls/f- guidelines.asp#kidney Accessed: March 20, 2012.
43. Scherr AJ, Lima J P, Sasse EC, et al. Adjuvant therapy for locally advanced renal cell cancer: a systematic review with meta-analysis. BMC Cancer 2011; 11: 115.
44. Bleumer I, Oosterwijk E, De Mulder P, Mulders P F. Immunotherapy for renal cell carcinoma. Eur Urol 2003; 44: 65-75.
45. Pizzocaro G, Piva L, Colavita M, et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 2001; 19: 425-31.
46. Clark JI, Atkins MB, Urba WJ, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 2003; 21: 3133-40.
47. Messing EM, Manola J, Wilding G, et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003; 21: 1214-22.
48. Passalacqua R, Buzio C, Buti S, et al. Adjuvant low-dose interleukin-2 (IL2) plus interferone-alpha (IFN) in operable renal cell cancer (RCC). A phase III, randomized, multicenter, independent trial of the Italian Oncology Group for Clinical Research (GOIRC). J Clin Oncol 2007; 25: 965s,
49. Hinotsu S, Kawai K, Ozono S, et al. Randomized controlled study of natural interferon a as adjuvant treatment for stage II or III renal cell carcinoma. Int J Clin Oncol 2011.[Epub ahead of print].
50. McDermott DF. Immunotherapy of metastatic renal cell carcinoma. Cancer 2009; 15: 115 Suppl 10: 2298-305.
51. Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999; 17: 2859-67.
52. Medical Research Council Renal Cancer Collaborators. Interferonalpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 1999; 353: 14-7.
53. Amato R. Modest effect of interferon alfa on metastatic renal-cell carcinoma. Lancet 1999; 353: 6-7.
54. Fisher RI, Rosenberg SA, Sznol M, et al. High-dose aldesleukin in renal cell carcinoma: Long-term survival update. Cancer J Sci Am 1997; 3: S70-2.
55. Galligioni E, Quaia M, Merlo A, et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year results of a prospective randomized study. Cancer 1996; 77: 2560-6.
56. Jocham D, Richter A, Hoffmann L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial. Lancet 2004; 363: 594-9.
57. Wood C, Srivastava P, Bukowski R, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 2008; 372: 145-54.
58. Passalacqua R, Buti S, Tomasello G, et al. Immunotherapy options in metastatic renal cell cancer: where we are and where we are going. Exp Rev Anticancer Ther 2006; 6: 1459-72.
59. Wood CG. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome. Clin Cancer Res 2007; 13: 697-702.
60. Doehn C, Richter A, Theodor RA, et al. An adjuvant vaccination with Reniale® prolongs survival in patients with renal cell carcinoma following radical nephrectomy: secondary analysis of a multicenter phase-III trial. J Urol 2007; 177: 167S,
61. Asakura T, Imai A, Ohkubo-Uraoka N, et al. Relationship between expression of drug-resistance factors and drug sensitivity in normal human renal proximal tubular epithelial cells in comparison with renal cell carcinoma. Oncol Rep 2005; 14: 601-7.
62. Waters JS, Moss C, Pyle L, et al. Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma. Br J Cancer 2004; 91: 1763-8.
63. Stadler WM, Halabi S, Rini BI, et al. A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. Cancer 2006; 107: 1273-9.
64. Lilleby W and Fossa SD. Chemotherapy in metastatic renal cell cancer. World J Urol 2005; 23: 175-9.
65. Masuda F, Nakada J, Kondo I, Furuta N. Adjuvant chemotherapy with vinblastine, adriamycin, and UFT for renal-cell carcinoma. Cancer Chemother Pharmacol. 1992; 30: 477-9.
66. Atzpodien J, Schmitt E, Gertenbach U, et al. Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoim-munotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 2005; 92: 843-6.
67. Pizzocaro G, Piva L, Salvioni R, et al. Adjuvant medroxyprogesterone acetate and steroid hormone receptors in category M0 renal cell carcinoma. An interim report of a prospective randomized study. J Urol 1986; 135: 18-21.
68. Pizzocaro G, Piva L, Di Fronzo G, et al. Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-Year results of a prospective randomized study. J Urol 1987; 138: 1379-81.
69. Margulis V, Matin S F, Tannir N, et al. Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma. Urology 2009; 73: 337-41.
70. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-34.
71. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-11.
72. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-81.
73. Motzer RJ, Hutson TE, Tomczak P, et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-56.
74. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-8.
75. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011; 378: 1931-9.
76. Plimack ER, Tannir N, Lin E, et al. Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures. Cancer 2009; 115: 1859-66.
77. Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumorangiogene-sis. Cancer Cell 2009; 15: 232-9.
78. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-31.
79. ClinicalTrials.gov [Internet]. Sunitinib or sorafenib in treating patients with kidney cancer that was removed by surgery. ClinicalTrials.gov registration number: NCT00326898. http://www.clinicaltrials.gov Accessed: March 20, 2012.
80. ClinicalTrials.gov [Internet]. Sorafenib in treating patients at risk of relapse after undergoing surgery to remove kidney cancer. ClinicalTrials.gov registration number: NCT00492258. http://www.clinicaltrials.gov Accessed: March 20, 2012.
81. ClinicalTrials.gov [Internet]. A clinical trial comparing efficacy and safety of sunitinib versus placebo for thetreatment of patients at high risk of recurrent renal cell cancer (S-TRAC). ClinicalTrials.gov registration number: NCT00375674. http://www.clinicaltrials.gov Accessed: March 20, 2012.
82. Liao SY, Aurelio ON, Jan K, et al. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res 1997; 57: 2827-31.
83. Lam JS, Leppert JT, Belldegrun AS, Figlin RA. Adjuvant therapy of renal cell carcinoma: patient selection and therapeutic options. BJU Int 2005; 96: 483-8.
84. Sokoloff MH, Daneshmand S, Ryan CW. Current clinical trials in renal cell carcinoma. Urol Oncol 2005; 23: 289-92.
85. ClinicalTrials.gov [Internet]. Monoclonal antibody therapy (Rencarex®) in treating patients who have undergone surgery for non-metastatic kidney cancer. ClinicalTrials.gov registration number: NCT00087022. http://www.clinicaltrials.gov Accessed: March 20, 2012.
86. ClinicalTrials.gov [Internet]. Everolimus in treating patients with kidney cancer who have undergone surgery. ClinicalTrials.gov registration number: NCT01120249. http://www.clinicaltrials.gov Accessed: March 20, 2012.
87. Homicsko K, Berthold DR. Neoadjuvant and adjuvant strategies in renal cell carcinoma: more questions than answers. Anticancer Drugs 2011; 22 Suppl 1: S4-8.
88. ClinicalTrials.gov [Internet]. A Study to evaluate pazopanib as an adjuvant treatment for localized renal cell carcinoma (RCC) (PROTECT). ClinicalTrials.gov registration number: NCT01235962. http://www.clinicaltrials. gov Accessed: March 20, 2012.
89. Rexer H. Adjuvante AUO-Studie beim Nierenzellkarzinom nach (Teil) Nephrektomie. Randomisierte, doppelblinde, placebokon-trollierte Phase-III-Studie (PROTECT - AN 30/10) zur Untersuchung der Wirksamkeit und Sicherheit von Pazopanib als adjuvante Therapie bei Patienten mit lokalisiertem oder lokal fortgeschrittenem Nierenzellkarzinom nach Nephrektomie. Urologe 2011; 50: 489-91.
90. Reeves DJ, Liu CY. Treatment of metastatic renal cell carcinoma. Cancer Chemother Pharmacol 2009; 64: 11-25.